# 21 U.S.C. 356c Discontinuance or interruption in the production of life-saving drugs

21 U.S.C. 356c Discontinuance or interruption in the production of life-saving drugs, “Discontinuance or interruption in the production of life-saving drugs”, is a U.S. Code section of [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-cceb-7622-a6eb-e8aae47a19b5>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0) › [Chapter 9—Federal Food, Drug, and Cosmetic Act](https://ontology.bommaritollc.com/id/01a0f06c-cb91-72e0-858b-060e8c845f23) › [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb) › [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 21 U.S.C. 356c](https://ontology.bommaritollc.com/id/01a0f06c-ccec-7349-b86e-869f08f90920)
- `eli:cites`:
  - [5 U.S.C. 552 Public information; agency rules, opinions, orders, records, and proceedings](https://ontology.bommaritollc.com/id/01a0edf4-5b27-7466-a019-fef93b12cea0)
  - [18 U.S.C. 1905 Disclosure of confidential information generally](https://ontology.bommaritollc.com/id/01a0f06a-9b21-77e5-b0e9-4b07425345ef)
  - [21 U.S.C. 321 Definitions; generally](https://ontology.bommaritollc.com/id/01a0f06c-cc8c-7030-ab68-1def0b197dcb)
  - [21 U.S.C. 353 Exemptions and consideration for certain drugs, devices, and biological products](https://ontology.bommaritollc.com/id/01a0f06c-cccb-7545-90e2-a1651be32192)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 356e Drug shortage list](https://ontology.bommaritollc.com/id/01a0f06c-ccee-7344-b4b7-63434c7ace97)
  - [21 U.S.C. 374 Inspection](https://ontology.bommaritollc.com/id/01a0f06c-cd83-7175-9624-79d9d7728390)
  - [21 U.S.C. 826 Production quotas for controlled substances](https://ontology.bommaritollc.com/id/01a0f06c-ceb9-70ea-9a63-151a3aefce3c)
  - [42 U.S.C. 247d Public health emergencies](https://ontology.bommaritollc.com/id/01a0f07c-d961-7148-9e7e-f0bbd971a175)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partA-sec356c](https://ontology.bommaritollc.com/id/01a0f06c-cceb-7622-a6eb-e8a9bf6ffb05)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f06c-d152-71b4-87f1-71d9deb092df)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-2d49-7745-9cd9-e5a952227fc9)
  - [evidence from https://www.govinfo.gov/link/uscode/21/356c?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f15-fe25-72f2-b601-7ca66d68380b)
- `schema:isPartOf`: [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d)
- `schema:legislationIdentifier`: 21 U.S.C. 356c
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Discontinuance or interruption in the production of life-saving drugs
- `schema:url`: [https://www.govinfo.gov/link/uscode/21/356c?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/21/356c?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 U.S.C. 356c Discontinuance or interruption in the production of life-saving drugs

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/21/356c?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partA-sec356c) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (6; `eli:cites`):
  - [21 CFR 314.81 Other postmarketing reports.](https://ontology.bommaritollc.com/id/01a0f094-c4c5-77fd-8c31-f5174052bb24)
  - [21 CFR 600.82 Notification of a permanent discontinuance or an interruption in manufacturing.](https://ontology.bommaritollc.com/id/01a0f094-cb29-77a6-be3d-cd638e0e824d)
  - [21 U.S.C. 356c-1 Annual reporting on drug shortages](https://ontology.bommaritollc.com/id/01a0f06c-ccec-7349-b86e-86a16137b916)
  - [21 U.S.C. 356d Coordination; task force and strategic plan](https://ontology.bommaritollc.com/id/01a0f06c-cced-70e5-a35f-16e13bc72425)
  - [21 U.S.C. 356e Drug shortage list](https://ontology.bommaritollc.com/id/01a0f06c-ccee-7344-b4b7-63434c7ace97)
  - [21 U.S.C. 374 Inspection](https://ontology.bommaritollc.com/id/01a0f06c-cd83-7175-9624-79d9d7728390)
- Amended by (4; `eli:amends`):
  - [Pub. L. 112-144](https://ontology.bommaritollc.com/id/01a0f06a-a3b6-70e5-8204-79bb2755f506)
  - [Pub. L. 114-255](https://ontology.bommaritollc.com/id/01a0ee1d-96d5-7151-84b6-b5e19f0e00ec)
  - [Pub. L. 116-136](https://ontology.bommaritollc.com/id/01a0ee05-7e19-7404-8801-c61defd83418)
  - [Pub. L. 117-328](https://ontology.bommaritollc.com/id/01a0edf4-a3b3-73ad-8a5b-366dfc33cea1)
- Rules made under it (3; `eli:based_on`):
  - [21 CFR Part 230—Certification and postmarketing reporting for designated medical gases (Eff. 12-18-25)](https://ontology.bommaritollc.com/id/01a0f094-b846-700a-99cf-b5ff460516cd)
  - [21 CFR Part 314—Applications for FDA approval to market a new drug](https://ontology.bommaritollc.com/id/01a0f094-b84d-7031-b149-cb632d656858)
  - [21 CFR Part 600—Biological products: general](https://ontology.bommaritollc.com/id/01a0f094-b881-7351-8dcb-945cb0a6d493)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 105-115](https://ontology.bommaritollc.com/id/01a0f06c-d29f-7443-a96a-3934363a8187)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-cceb-7622-a6eb-e8aae47a19b5.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-cceb-7622-a6eb-e8aae47a19b5.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-cceb-7622-a6eb-e8aae47a19b5.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-cceb-7622-a6eb-e8aae47a19b5)
Cite as: 21 U.S.C. 356c Discontinuance or interruption in the production of life-saving drugs. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-cceb-7622-a6eb-e8aae47a19b5
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
